FoxM1 mediated resistance to gefitinib in non-smallcell lung cancer cells

AIM: Gefitinib is effective in only approximately 20% of patients with non-small-cell lung cancer (NSCLC), and the underlying mechanism remains unclear. FoxM1 is upregulated in NSCLC and associated with a poor prognosis in NSCLC patients. In this study, we examined the possible role of FoxM1 in gefi...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Xu, Nuo, Zhang, Xin, Wang, Xun, Ge, Hai-yan, Wang, Xiao-ying, Garfield, David, Yang, Ping, Song, Yuan-lin, Bai, Chun-xue
Formato: Artigo
Idioma:Inglês
Publicado: Nature Publishing Group 2012
Assuntos:
Original Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC4010351/
https://ncbi.nlm.nih.gov/pubmed/22447226
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/aps.2011.188
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares